Evozyne
AI-driven biotech company engineering novel proteins for therapeutics and sustainability.
About
Evozyne designs novel therapeutic proteins using generative AI to address challenges in immune-mediated diseases. Their AI-native platform, EvoGen, creates new protein mechanisms optimized for potency, stability, and specificity, which are then built and tested in their EvoLab facility. Evozyne translates these engineered proteins into their pipeline for immune therapies, serving patients with high unmet needs where current treatments fail.
Key facts
At-a-glance profile data
- Website
- evozyne.com
- Headquarters
- Chicago, United States
- Founded
- 2020
- Employees
- 54
- Total funding
- $135M (Series B)
- Business model
- B2B
- Tags
- BiotechnologyAIDrug DiscoveryGenerative AIProtein Engineering
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 27 Sept 2023 | Series B | $81M | OrbiMed, Fidelity Investments |
| 21 Apr 2021 | Series A | $54M | - |
Tech stack
Detected on evozyne.com, last scanned 18 Sept 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Mimecast
Frequently asked
How much funding has Evozyne raised?
Evozyne has raised a total of $135M in funding. The most recent round on record is Series B.
How many employees does Evozyne have?
Evozyne has approximately 54 people on record.